Pulmonary effects of nanofibrillated celluloses in mice suggest that carboxylation lowers the inflammatory and acute phase responses

We studied if the pulmonary and systemic toxicity of nanofibrillated celluloses can be reduced by carboxylation. Nanofibrillated celluloses administered at 6 or 18 μg to mice by intratracheal instillation were: 1) FINE NFC, 2–20 μm in length, 2–15 nm in width, 2) AS (−COOH), carboxylated, 0.5–10 μm in length, 4–10 nm in width, containing the biocide BIM MC4901 and 3) BIOCID FINE NFC: as (1) but containing BIM MC4901. FINE NFC administration increased neutrophil influx in BAL and induced SAA3 in plasma. AS (−COOH) produced lower neutrophil influx and systemic SAA3 levels than FINE NFC. Results obtained with BIOCID FINE NFC suggested that BIM MC4901 biocide did not explain the lowered response. Increased DNA damage levels were observed across materials, doses and time points. In conclusion, carboxylation of nanofibrillated cellulose was associated with reduced pulmonary and systemic toxicity, suggesting involvement of OH groups in the inflammatory and acute phase responses.     

THE MEASUREMENT OF GLOMERULAR BLOOD FLOW IN THE RAT KIDNEY: INFLUENCE OF MICROSPHERE SIZE

1. Radioactively labelled microspheres were used to determine glomerular blood flow in glomerular populations with distinct vascular characteristics. Two batches of microspheres (15 ± 5.0 μm diameter and 7.0–10 μm diameter) were utilized. 2. The results show that the larger microspheres overestimate the superficial glomerular blood flow (414 ± 61 nl/min, mean ± s.e.m.) and underestimate the deep glomerular blood flow (98 ± 10 nl/min), when compared with the data obtained with 7.0–10 μm diameter microspheres (317 ± 30 nl/min and 209 ± 23 nl/min, respectively). 3. The rheological artefact associated with the use of larger microspheres is confirmed by finding an uneven size distribution of microspheres lodged in the glomeruli. In each of three experiments, the mean diameter of 200 microspheres lodged in the superficial glomeruli (16.43 ± 0.27 μm, 15.87 ± 0.23/mi and 16.58 ± 0.27 Jim) was significantly greater than that found in the deep glomeruli (15.36 ± 0.15μm, 15.25 ± 0.21 μm and 15.73 ± 0.24μm; P<0.01, <0.05 and < 0.01, respectively). No such difference was detected when the 7.0–10 μm spheres were used. 4. Glomerular blood flow can be measured at all depths of the rat's cortex and the demonstrated rheological artefact associated with use of the larger spheres is circumvented with the use of 7.0–10 μm microspheres.     

Comparison of a Respiratory Suspension Aerosolized by an Air-Jet and an Ultrasonic Nebulizer

ABSTRACT

In the absence of USP standards and performance monographs, this research sought to determine if differences in the aerosolization mechanism (air-jet vs. ultrasonic) affected droplet and insoluble particle deposition of a nebulized model respiratory suspension. Five milliliters of a model suspension containing 0.1% w/v flourescein (to estimate droplet deposition) and known quantities of 1, 3, and 6 μm latex spheres (representing insoluble drug particles) was aerosolized from an air-jet and an ultrasonic nebulizer. Nebulized output was collected in a modified Andersen impactor. Samples were analyzed spectrophotometrically (490.5 nm) and by a Coulter Counter to estimate droplet and sphere deposition, respectively. The distribution of droplets throughout the modified impactor for both nebulizers suggested that both the air-jet and the ultrasonic nebulizer produced droplets (0.4 to 10 μm in aerodynamic diameter) large enough to incorporate 1, 3, and 6 μm insoluble spheres. However, Coulter Counter analysis of the sphere distribution revealed that while the air-jet nebulized output contained spheres of all sizes, this was not true for the ultrasonic nebulizer. In the ultrasonic nebulizer, 99% of the spheres (irrespective of size) were not aerosolized and were recovered from the nebulizer reservoir at the aerosolization end point. The results highlight the importance of evaluating performance of a respiratory suspension in combination with a specific nebulizer. When conducting in vitro inertial deposition testing of a respiratory suspension, it is inappropriate to assume that deposition trends of droplets will predict the deposition of the insoluble dispersed phase.     

Controlled micro release of pharmacological agents: measurements of volume ejected in vitro through fine tipped glass microelectrodes by pressure.

The amounts of substances delivered by applying pressure to fine. Theta-type, fluid-filled glass microelectrodes were quantitated by in vitro measurement. Relationships between the volumes ejected, the duration of pressure application, and tip size were investigated. The tip sizes ranged between ? 0.6 and 1.2 μm o.d. and were suitable for recording intracellularly from cortical neurons in awake cats.With electrodes of tip sizes ? 0.6 μm, the volumes of fluid ejected increased linearly with time. Volumes were determined by measuring the activity of ejected radio isotopes or the size of droplets of an aqueous solution expressed into mineral oil. Measurements were obtained over periods of up to 180 sec of pressure application (80 psi). The volumes expressed ranged between 10¹?10⁵ μm³. The rate of ejection increased as the tip size increased. Tips of 0.6 μm passed up to 2 × 10² μm³; 0.9 μm, up to 4 × 10³ μm³ and 1.2 μm up to 5 × 10⁴ μm³ volumes for 30 sec of pressure application. The output rate was greater for ejections of ethanolic solution than for aqueous solution.The repeatability of ejection from individual electrodes was also tested. Relatively consistent, reproducible delivery was found for electrodes with tips between 0.6 and 1.2 μm. The results suggest that the pressure microinjection method affords more predictable, quantitative delivery than the iontophoretic method. Femtomolar (10^?15 M) amounts of pharmacologically active substances can be administered by such means.     

Safe-by-design strategies for lowering the genotoxicity and pulmonary inflammation of multiwalled carbon nanotubes: Reduction of length and the introduction of COOH groups

Potentially, the toxicity of multiwalled carbon nanotubes (MWCNTs) can be reduced in a safe-by-design strategy. We investigated if genotoxicity and pulmonary inflammation of MWCNTs from the same batch were lowered by a) reducing length and b) introducing COOH-groups into the structure. Mice were administered: 1) long and pristine MWCNT (CNT-long) (3.9 μm); 2) short and pristine CNT (CNT-short) (1 μm); 3) CNT modified with high ratio COOH-groups (CNT-COOH-high); 4) CNT modified with low ratio COOH-groups (CNT-COOH-low). MWCNTs were dosed by intratracheal instillation at 18 or 54 μg/mouse (∼0.9 and 2.7 mg/kg bw). Neutrophils numbers were highest after CNT-long exposure, and both shortening the MWCNT and addition of COOH-groups lowered pulmonary inflammation (day 1 and 28). Likewise, CNT-long induced genotoxicity, which was absent with CNT-short and after introduction of COOH groups. In conclusion, genotoxicity and pulmonary inflammation of MWCNTs were lowered, but not eliminated, by shortening the fibres or introducing COOH-groups.     

Zonisamide attenuates MPTP neurotoxicity in marmosets

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces parkinsonism in humans and animals. The effects of zonisamide on dopamine neurons were studied in MPTP-treated common marmosets (Callithrix jacchus). Groups of animals (n = 3) were treated with MPTP (2.5 mg/kg, every 24 h x 3); MPTP plus zonisamide (40 mg/kg administered 1 h before each MPTP dose); MPTP plus selegiline (a known MAO-B inhibitor) (2 mg/kg administered 1 h before each MPTP dose); and saline controls. An immunohistochemical study of the substantia nigra was performed 14 days after MPTP treatment in each group. MPTP reduced the mean number of tyrosine hydroxylase (TH)-positive neurons to 10% of the normal control group and mean cell size was significantly (P < 0.001) reduced from 424 to 159 μm2. In the group pre-treated with zonisamide, the mean number of TH-positive neurons was reduced to 26% of that in the normal control group and the mean neuron size was significantly (P < 0.05) increased from 159 to 273 μm2 compared with the group treated with MPTP alone. Moreover, in the group pre-treated with selegiline, the mean number of TH-positive neurons was 47% of that in the normal control group and the mean neuron size was increased significantly (P < 0.01) from 159 to 319 μm2 compared to the group treated with MPTP alone. This observation suggests that zonisamide reduces MPTP toxicity.     

Sensitivity of early mouse embryos to methylmercury toxicity

The sensitivity of early mouse embryos to mercury toxicity was studied in vitro by treating them with methylmercuric chloride (MMC) and examining their developmental potential. It was found that MMC exerted acute effects at high concentrations (1 to 2 μm) by arresting preimplantation development or by collapsing blastocoels. At a lower concentration (0.5 μm), MMC did not affect preimplantation development but interfered with development of the inner cell mass (ICM). The acute effect of MMC was most severe on blastocysts and least severe on morulae. When blastocysts were treated for 24 hr, 95 and 100% of them collapsed during treatment with MMC at 1 and 2 μm, respectively. Most of the collapsed blastocysts did not develop any further. By contrast, 32% (not significantly different from control) and 50% of morulae failed to develop into blastocysts during treatment with 1 and 2 μm MMC, respectively. The sensitivity of two-cell and four- to eight-cell embryos to the acute effect of MMC fell between that of morulae and blastocysts: When they were treated with 2 μm MMC, none of the embryos developed into blastocysts, but at an MMC concentration of 1 μm, 64% of two-cell embryos and 73% of four- to eight-cell embryos failed to form blastocysts. Delayed effects of MMC on trophoblast outgrowth and ICM development were also least severe after treatment of morulae but similar after treatment at all other stages. When two-cell embryos were exposed to MMC for 3 days or when late blastocysts were exposed for 5 days, 0.25 or 0.125 μm, respectively, was sufficient to interfere with development of the ICM. These results indicated that early mouse embryos are highly sensitive to mercury toxicity and that the sensitivity changes as they develop.     

Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day x 14 days every 4 weeks. A total of 79 complete cycles was administered. Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer.     

Phase I study of paclitaxel administered by ten-day continuous infusion

PURPOSE: Pre-clinical data have suggested that prolonged exposure to paclitaxel enhances its cytotoxicity, but various clinical trials utilizing long-term infusions of paclitaxel have been limited by unacceptable hematologic toxicity, most notably significant neutropenia. A phase I study of paclitaxel administered over 10 days, was performed to evaluate the hematologic and non-hematologic toxicities as well as to determine the maximum-tolerated dose for the 10-day infusion duration. PATIENTS AND METHODS: Twenty-nine solid tumor patients (predominantly non-small cell lung cancer and head and neck cancer) were treated with paclitaxel at doses ranging from 5 mg/m2/day to 25 mg/m2/day administered as a 10-day continuous infusion via a pump every 21 days. Dose escalation was permitted within individual patients. Dose-limiting toxicity (DLT) was defined as grade 3 or 4 non-hematologic toxicity, ANC < or = 500 or platelet count < or = 25,000 for > or = 7 days or febrile neutropenia. The maximum tolerated dose (MTD) was defined as the highest dose level at which less than two out of six patients developed DLT. All of the patients had received prior chemotherapy; approximately two-thirds had received prior radiation as well. All patients received standard pre-medications for paclitaxel, including anti-histamines and corticosteroids. Prophylactic granulocyte colony-stimulating factor (G-CSF) was not used. RESULTS: A total of 110 courses of paclitaxel were administered to 29 patients. The incidence of hematologic and non-hematologic toxicity was quite low among the patients treated at dose levels below 17 mg/m2/day. At higher doses, non-hematologic toxicities including arthralgias, myalgias, fatigue, nausea, stomatitis, and peripheral neuropathy were seen, although nearly all of the toxicities were less than grade 3 (NCI toxicity criteria). Hematologic toxicity mostly consisted of neutropenia and was more common at dose levels of 17 mg/m2/day or higher. Nevertheless, even at the highest dose levels (21 mg/m2/day and 25 mg/m2/day) grade 3 or 4 neutropenia occurred in only 50% of patients. Dose-limiting hematologic toxicity occurred in 2 of 4 patients treated at the 25 mg/m2/day dose level. CONCLUSION: Paclitaxel can be safely administered as a 10-day infusion. The MTD for this schedule is 210 mg/m2. Unlike the 96-hour paclitaxel infusions, dose-reduction for myelosuppression may not be necessary because the MTD of paclitaxel when administered over a 10-day infusion is similar to the MTD of paclitaxel when infused over 3 or 24 hours.     

Phase I study of paclitaxel administered by ten-day continuous infusion

Purpose: Pre-clinical data have suggested that prolonged exposure to paclitaxel enhances its cytotoxicity, but various clinical trials utilizing long-term infusions of paclitaxel have been limited by unacceptable hematologic toxicity, most notably significant neutropenia. A phase I study of paclitaxel administered over 10 days, was performed to evaluate the hematologic and non-hematologic toxicities as well as to determine the maximum-tolerated dose for the 10-day infusion duration.Patients and methods: Twenty-nine solid tumor patients (predominantly non-small cell lung cancer and head and neck cancer) were treated with paclitaxel at doses ranging from 5 mg/m2/day to 25 mg/m2/day administered as a 10-day continuous infusion via a pump every 21 days. Dose escalation was permitted within individual patients. Dose-limiting toxicity (DLT) was defined as grade 3 or 4 non-hematologic toxicity, ANC 500 or platelet count 25,000 for 7 days or febrile neutropenia. The maximum tolerated dose (MTD) was defined as the highest dose level at which less than two out of six patients developed DLT. All of the patients had received prior chemotherapy; approximately two-thirds had received prior radiation as well. All patients received standard pre-medications for paclitaxel, including anti-histamines and corticosteroids. Prophylactic granulocyte colony-stimulating factor (G-CSF) was not used.Results: A total of 110 courses of paclitaxel were administered to 29 patients. The incidence of hematologic and non-hematologic toxicity was quite low among the patients treated at dose levels below 17 mg/m2/day. At higher doses, non-hematologic toxicities including arthralgias, myalgias, fatigue, nausea, stomatitis, and peripheral neuropathy were seen, although nearly all of the toxicities were less than grade 3 (NCI toxicity criteria). Hematologic toxicity mostly consisted of neutropenia and was more common at dose levels of 17 mg/m2/day or higher. Nevertheless, even at the highest dose levels (21 mg/m2/day and 25 mg/m2/day) grade 3 or 4 neutropenia occurred in only 50% of patients. Dose-limiting hematologic toxicity occurred in 2 of 4 patients treated at the 25 mg/m2/day dose level.Conclusion: Paclitaxel can be safely administered as a 10-day infusion. The MTD for this schedule is 210 mg/m2. Unlike the 96-hour paclitaxel infusions, dose-reduction for myelosuppression may not be necessary because the MTD of paclitaxel when administered over a 10-day infusion is similar to the MTD of paclitaxel when infused over 3 or 24 hours.     

Absence of prenatal developmental toxicity from inhaled arsenic trioxide in rats.

A review of the literature revealed no published inhalational developmental toxicity studies of arsenic performed according to modern regulatory guidelines and with exposure throughout gestation. In the present study, inorganic arsenic, as arsenic trioxide (As(+3), As2O3), was administered via whole-body inhalational exposure to groups of twenty-five Crl:CD(SD)BR female rats for six h per day every day, beginning fourteen days prior to mating and continuing throughout mating and gestation. Exposures were begun prior to mating in order to achieve a biological steady state of As(+3) in the dams prior to embryonal-fetal development. In a preliminary exposure range-finding study, half of the females that had been exposed to arsenic trioxide at 25 mg/m3 died or were euthanized in extremis. In the definitive study, target exposure levels were 0.3, 3.0, and 10.0 mg/m3. Maternal toxicity, which was determined by the occurrence of rales, a decrease in net body weight gain, and a decrease in food intake during pre-mating and gestational exposure, was observed only at the 10 mg/m3 exposure level. Intrauterine parameters (mean numbers of corpora lutea, implantation sites, resorptions and viable fetuses, and mean fetal weights) were unaffected by treatment. No treatment-related malformations or developmental variations were noted at any exposure level. The no-observed-adverse-effect level (NOAEL) for maternal toxicity was 3.0 mg/m3; the NOAEL for developmental toxicity was greater than or equal to 10 mg/m3, 760 times both the time-weighted average threshold limit value (TLV) and the permissible exposure limit (PEL) for humans. Based on the results of this study, we conclude that arsenic trioxide, when administered via whole-body inhalation to pregnant rats, is not a developmental toxicant.     

Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered.Two of 18 evaluable patients (11.1%) had decreases in PSA lasting five and eight months. No objective responses or improvement in bone scans was noted. The major toxicity observed was diarrhea. Although circadian infusion FUDR is feasible and tolerable, it has limited activity in hormone refractory prostate cancer.     

Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme

The aim of this study was to assess the efficacy and toxicity of a combination of dacarbazine (D) and fotemustine (F) administered to a homogenous group of patients with recurrent or progressive glioblastoma multiforme (GBM). Thirty-one patients with computed tomography or magnetic resonance imaging scan evidence of recurrent or progressive GBM after first-line chemotherapy with nitrosoureas as well as radiation therapy were given a combination of D (200 mg/m2) and F (100 mg/m2). At 30 min after termination of D administration, F was given over 60 min. Treatment was performed in an outpatient setting every 21 days. A total of 140 cycles (range 1-12 cycles; median 4 cycles) was administered. One partial response (3%) lasting for 11 weeks was observed. Sixteen (52%) patients reached stable disease lasting between 7 and 94 weeks. Median survival from start of the D/F combination was 45 (range 10-150) weeks. Median time to progression was 17 (3-101) weeks for all patients. Major toxicity was myelosuppression resulting in exclusion from study in seven (23%) patients [due to thrombocytopenia common toxicity criteria (CTC) grade 2 persisting longer than 3 weeks in three patients, due to thrombocytopenia CTC grade >/=3 in three and due to leukopenia CTC grade 3 in one patient]. No other toxicity than alopecia occurred. We conclude that the D/F combination is a well-tolerated second-line regimen and can be administered in a complete outpatient setting. D/F shows efficacy even in nitrosourea-pretreated patients and justifies further investigation.     

Investigation of 1-(4-morpholinophenyl)-3-(4-fluorophenyl)-propenone and 1-(4-morpholinophenyl)-3-(3-fluorophenyl)-propenone as new apoptosis inducers on Spodoptera frugiperda (Sf9) cells

The objective of this study was to examine the toxicity of 1-(4-morpholinophenyl)-3-(4-fluorophenyl)-propenone (A) and 1-(4-morpholinophenyl)-3-(3-fluorophenyl)-propenone (B) on Spodoptera frugiperda (Sf9) cells and the mechanism of the toxicity. By cell-based thiazolyl blue tetrazolium bromide (MTT) assay, we found that the IC(50) were 35.45 μM for A and 31.97 μM for B respectively. Formation of apoptotic bodies was observed at 24?h in the treated cells. There was a significant increase of DNA ladders in the treated Sf9 cells compared to controls. In the presence of 50 μM compound A and B for 24?h, ATP content of Sf9 cells reduced by approximately 50%. Compared to the controls, the significant over-expression of caspase-3 in treated cells was measured by caspase-3 activity kit, and the loss of mitochondrial membrane potential (ΔΨm) was detected in apoptosis cells. The results suggested that the two compounds could be identified as new potent cell apoptosis inducers.     

Response to Dr. Morfeld's Letter

Abstract

The biopersistence of airborne fibers is felt to play an important role in their potential toxicity. Since the dissolution rate of fibers can be measured in cell-free systems, the current study was undertaken to determine if the dissolution rate of fibers in the lung was related to the dissolution rate of fibers in vitro, and whether dissolution serves to remove fibers from the lung. To determine dissolution rates in vivo, suspensions of fibers were administered to rats by intratracheal instillation, and the numbers, lengths, and diameters of fibers recovered from the lungs at intervals up to 1 yr after administration were measured by phase-contrast optical microscopy. Five different glass fibers were used that had dissolution rates ranging from 2 to 600 ng/cm²/h measured in vitro in simulated lung fluid at pH 7.4. Examination of the diameter distributions of fibers longer than 20 μm showed that the peak diameter decreased steadily with time after instillation, at the same rate measured for each fiber in vitro, until it approached zero. Measurements of the total number of fibers remaining in the rats' lungs at times up to 1 yr after instillation suggest that not many of the administered fibers were being cleared by macrophage-mediated transport via the conducting airways. A computer simulation of the fibers in the lungs was performed in which each of the administered long fibers (20 μm or longer) was decreased in diameter according to the rate measured in vitro, while the short fibers (less than 20 μm long) were unaffected. The ratio of long to short fibers predicted by this simulation agreed well with this quantity measured from the fibers recovered from the rats' lungs at each time interval after instillation. It was concluded that long glass fibers, at least those longer than 20 μm, are removed from the lung by dissolution at much the same rate measured in vitro.     

Investigation of 1-(4-morpholinophenyl)-3-(4-fluorophenyl)-propenone and 1-(4-morpholinophenyl)-3-(3-fluorophenyl)-propenone as new apoptosis inducers on Spodoptera frugiperda (Sf9) cells

The objective of this study was to examine the toxicity of 1-(4-morpholinophenyl)-3-(4-fluorophenyl)-propenone (A) and 1-(4-morpholinophenyl)-3-(3-fluorophenyl)-propenone (B) on Spodoptera frugiperda (Sf9) cells and the mechanism of the toxicity. By cell-based thiazolyl blue tetrazolium bromide (MTT) assay, we found that the IC₅₀ were 35.45 μM for A and 31.97 μM for B respectively. Formation of apoptotic bodies was observed at 24?h in the treated cells. There was a significant increase of DNA ladders in the treated Sf9 cells compared to controls. In the presence of 50 μM compound A and B for 24?h, ATP content of Sf9 cells reduced by approximately 50%. Compared to the controls, the significant over-expression of caspase-3 in treated cells was measured by caspase-3 activity kit, and the loss of mitochondrial membrane potential (ΔΨm) was detected in apoptosis cells. The results suggested that the two compounds could be identified as new potent cell apoptosis inducers.     

Uptake and efflux of 14C-paraquat by rat lung slices: the effect of imipramine and other drugs.

Paraquat accumulation by rat lung slices incubated at 10 or 100 μm concentration was linear with time and the accumulated paraquat was “noneffluxable.” Imipramine (100 or 500 μm) inhibited paraquat (10 μm) uptake by 38 and 85%, respectively, and 500 μm imipramine enhanced paraquat efflux by 40%. The combination of impaired uptake and enhanced efflux suggested the possibility that imipramine might reduce the toxicity of paraquat in intact animals. However, at the doses used, imipramine did not alter paraquat toxicity in vivo. Eleven other drugs were shown to inhibit uptake, but only five enhanced paraquat efflux.     

Benzothiazole toxicity assessment in support of synthetic turf field human health risk assessment

Synthetic turf fields cushioned with crumb rubber may be a source of chemical exposure to those playing on the fields. Benzothiazole (BZT) may volatilize from crumb rubber and result in inhalation exposure. Benzothiazole has been the primary rubber-related chemical found in synthetic turf studies. However, risks associated with BZT have not been thoroughly assessed, primarily because of gaps in the database. This assessment provides toxicity information for a human health risk assessment involving BZT detected at five fields in Connecticut. BZT exerts acute toxicity and is a respiratory irritant and dermal sensitizer. In a genetic toxicity assay BZT was positive in Salmonella in the presence of metabolic activation. BZT metabolism involves ring-opening and formation of aromatic hydroxylamines, metabolites with mutagenic and carcinogenic potential. A structural analogue 2-mercaptobenzothiazole (2-MBZT) was more widely tested and so is used as a surrogate for some endpoints. 2-MBZT is a rodent carcinogen with rubber industry data supporting an association with human bladder cancer. The following BZT toxicity values were derived: (1) acute air target of 110 μg/m(3) based upon a BZT RD(50) study in mice relative to results for formaldehyde; (2) a chronic noncancer target of 18 μg/m(3) based upon the no-observed-adverse-effect level (NOAEL) in a subchronic dietary study in rats, dose route extrapolation, and uncertainty factors that combine to 1000; (3) a cancer unit risk of 1.8E-07/μg-m(3) based upon a published oral slope factor for 2-MBZT and dose-route extrapolation. While there are numerous uncertainties in the BZT toxicology database, this assessment enables BZT to be quantitatively assessed in risk assessments involving synthetic turf fields. However, this is only a screening-level assessment, and research that better defines BZT potency is needed.     

Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma

Methotrexate (MTX) is the chemotherapeutic for which the serum levels can be detected. If the MTX level is detected in time, high toxicity risk can be decreased. In this study, intermediate doses of MTX (1 g/m2) infusions are administered to B-cell non-Hodgkin lymphoma patients between 3 and 13 years old. The toxicity of MTX in accordance with serum levels and the toxicity of other combined drugs are investigated. Blood samples were collected consecutively, and MTX levels were detected by high-performance liquid chromatography. When hematological, gastrointestinal, and renal toxicity scores were compared with the 24-h serum levels of MTX, they showed a significant positive correlation. Hematological toxicity scores increased by Ifosfamide, Etoposide, and Cytarabine combined with MTX without altering the serum levels. Antibiotic combination with MTX has no effect on the toxicity scores. In conclusion, if MTX is combined with other myelosuppressive, hepatotoxic, and nephrotoxic drugs, the measurement of MTX serum levels alone is not a sufficient parameter to show the toxicity.     

Depression of myocardial contractility in acute iron toxicity in rabbits

The hemodynamic effects of acute iron toxicity were evaluated in rabbits. A lethal dose of iron (200 mg/kg as ferrous sulfate) was administered into the duodenum of seven rabbits as heart rate, right atrial pressure, arterial pressure, cardiac output, left ventricular pressure, right ventricular developed force, and arterial pH were monitored. Hemodynamic variables were compared to those in a control group of animals (n = 7; no iron) and to those in a group of animals (n = 7) receiving the same dose of iron but with the addition of an iv infusion of sodium bicarbonate to prevent iron-induced acidosis. Our results demonstrate that an acute lethal dose of iron in the rabbit: (1) increases systemic vascular resistance, (2) does not alter filling pressure of either the right or left ventricle, and (3) depresses stroke volume, cardiac output, right ventricular force, and left ventricular $\text{dP}\text{dt}$. Prevention of acidosis does not prevent the hemodynamic alterations induced by the administration of iron. We conclude that acute iron toxicity significantly depresses myocardial contractility. Diminished myocardial contractility appears to be important in the pathogenesis of iron-induced shock in the rabbit.